Third quarter year-over-year revenue growth of 45%; executed Master Alliance Agreement with GE Healthcare
BOSTON and LAUSANNE, Switzerland, November 10, 2021 — SOPHiA GENETICS SA (Nasdaq: SOPH), today reported financial results for the third quarter ended September 30, 2021.
Recent Highlights
- Revenue was $10.4 million for the third quarter, representing a 45% increase over the corresponding period of 2020
- Following a previous letter of intent with GE Healthcare, executed a final Master Alliance Agreement under which we will be working together with GE on a variety of oncology opportunities in the healthcare market and will collaborate on different initiatives and projects
t to maximize support for Agilent customers in automating their next generation sequencing (NGS) workflows with enhanced, cutting-edge interpretation tools for germline and cancer applications.